SEOUL, South Korea, May 29, 2025 /PRNewswire/ --Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful ...

Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, ...

Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC) ...

Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes. Detection of ...

SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® ...

Dendritic cells are part of our innate immune system and occupy a central position there. "These cells are particularly good at initiating an effective T-cell-mediated immune response of the acquired ...

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...

Molecular analysis identified ABC and GCB subtypes, with the ABC subtype benefiting more from the new regimen. The identification of biomarkers in frontline diffuse large B-cell lymphoma (DLBCL) is ...

AFM24 shows improved response rates and progression-free survival in NSCLC, with higher exposure correlating to better outcomes in patients. Affimed N.V. announced findings from an exposure-outcome ...